Formulation and characterization of nanoliposomal 5-fluorouracil for cancer nanotherapy

被引:42
作者
ElMeshad, A. N. [1 ]
Mortazavi, S. M. [2 ]
Mozafari, M. R. [3 ]
机构
[1] Cairo Univ, Dept Pharmaceut & Ind Pharm, Fac Pharm, Cairo, Egypt
[2] Kurdestan Univ, Fac Med, Med Sch Sanandaj, Biochem Grp, Sanandaj, Kurdestan, Iran
[3] Monash Univ LPO, Australasian Nanosci & Nanotechnol Initiat, Clayton, Vic 3800, Australia
关键词
Cancer nanotherapy; 5-fluoruracil; heating method; lipid vesicles; transmission electron microscope; CELL LUNG-CANCER; DRUG-DELIVERY; VESSEL LEAKINESS; DNA COMPLEXES; LIPOSOMES; CHEMOTHERAPY; STABILITY; TOXICITY; INFUSION; SYSTEMS;
D O I
10.3109/08982104.2013.810644
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A scalable and safe method was developed to prepare nanoliposome carriers for the entrapment and delivery of 5-fluorouracil (5-FU). The carrier systems were composed of endogenously occurring dipalmitoylphosphatidylcholine (DPPC), negatively charged dicetylphosphate (DCP), cholesterol (CHOL) and glycerol (3%, v/v). Nanoliposomes were prepared by the heating method in which no harmful chemical or procedure is involved. Results indicated fast and reproducible formation of non-toxic liposomes that possess high entrapment efficiency (up to 96.9%) and vesicle size range of ca. 530-620 nm. Transmission electron and optical micrographs of the 5-FU liposomes revealed that they were spherical and some were multilayered. There was an increase in the release rate of 5-FU from the liposomes prepared with a high ratio of drug: lipid. The release data showed that the highest release rates were obtained for nanoliposomes containing 5-FU with the drug concentration of 500 mM and that it followed the diffusion model. Nanoliposome preparation method introduced here has the potential of large-scale manufacture of safe and efficient carriers of 5-FU.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 66 条
[51]  
Namdeo A, 1999, J MICROENCAPSUL, V16, P731
[52]  
Omidi Yadollah, 2005, Current Drug Delivery, V2, P429, DOI 10.2174/156720105774370249
[53]   PREPARATION AND STABILITY OF LIPOSOMES CONTAINING 5-FLUOROURACIL [J].
OZER, AY ;
TALSMA, H .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1989, 55 (2-3) :185-191
[54]  
Ozer AY., 1992, DRUG TARGET DELIV, V1, P151
[55]  
Patel V.B., 2011, INT J CHEM ANAL SCI, V2, P97
[56]   PROLONGED RETENTION OF HIGH-CONCENTRATIONS OF 5-FLUOROURACIL IN HUMAN AND MURINE TUMORS AS COMPARED WITH PLASMA [J].
PETERS, GJ ;
LANKELMA, J ;
KOK, RM ;
NOORDHUIS, P ;
VANGROENINGEN, CJ ;
VANDERWILT, CL ;
MEYER, S ;
PINEDO, HM .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 31 (04) :269-276
[57]  
REINECCIUS G, 1995, ENCAPSULATION CONTRO, P113
[58]  
Rudy BC, 1973, ANAL PROFILES DRUG S, P221
[59]  
Shanyang L., 1988, Journal of pharmaceutical sciences, V77, P229
[60]   Development of inhalational agents for oncologic use [J].
Sharma, S ;
White, D ;
Imondi, AR ;
Placke, ME ;
Vail, DM ;
Kris, MG .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1839-1847